Viemed Launches 5% Buyback Program to Repurchase 1.93M Shares by March 2027
Viemed Healthcare’s Board authorized a normal course issuer bid through March 2027 to repurchase up to 1,930,131 shares, or about 5% of outstanding stock, via open market or block purchases. The company reported record 2025 revenue and Adjusted EBITDA, more than doubling free cash flow and exiting the year with zero net debt.
1. Program Details
Viemed’s Board authorized a share repurchase program effective through March 2027 under Canadian normal course issuer bid rules. The Company may acquire up to 1,930,131 common shares, representing approximately 5% of issued shares, via open market or block purchases, with daily limits set at 25% of average trading volume.
2. 2025 Financial Performance
In 2025, Viemed delivered record annual revenue and Adjusted EBITDA, more than doubled free cash flow year over year, and reported effectively zero net debt at year-end. The Company also held $13.5 million in cash alongside substantial availability under its credit facilities to support ongoing operations and capital allocation.
3. Capital Allocation Strategy
This is Viemed’s fourth repurchase program, following three prior bids that returned approximately $26.3 million to shareholders through the retirement of around 4.5 million shares. Management views buybacks as an opportunistic component of its broader strategy, balancing share repurchases with investments in organic growth and selected acquisitions.